Trial Profile
A Prospective, Comparative, Randomized, Multicenteric, Phase III study of Rituximab in Patients with NHL
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 31 Aug 2016
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Intas Biopharmaceuticals
- 18 Apr 2012 New trial record